What are Nexlizet and Repatha used for?
Nexlizet is a cholesterol-lowering prescription medicine that combines bempedoic acid with ezetimibe. It’s used to help lower LDL (“bad”) cholesterol, typically in people who need additional LDL reduction beyond statins or who can’t take statins.
Repatha (evolocumab) is a PCSK9 inhibitor given by injection. It’s also used to lower LDL cholesterol, including in people with established cardiovascular disease or familial hypercholesterolemia, or other high-risk groups needing substantial LDL lowering.
How do Nexlizet and Repatha lower LDL cholesterol differently?
Nexlizet targets LDL reduction through oral, cholesterol-absorption and liver cholesterol-processing pathways by combining:
- Ezetimibe (reduces intestinal cholesterol absorption)
- Bempedoic acid (acts in the liver to reduce cholesterol synthesis upstream of HMG-CoA reductase)
Repatha uses a different mechanism: it’s a monoclonal antibody that binds PCSK9 and helps the liver clear more LDL from the blood.
Because the mechanisms differ, they can be complementary in some treatment plans, depending on guideline goals, prior therapies, and tolerability.
Which one is a better option for lowering LDL—oral pill or injection?
There isn’t enough information here to rank “better” in all patients, because real-world choice depends on:
- how low the LDL target needs to be
- what other lipid drugs the patient already takes
- medication tolerability and adherence
- insurance coverage and prior authorization requirements
In general terms, Nexlizet is an oral option built on bempedoic acid plus ezetimibe, while Repatha is a PCSK9 injection option used when patients need significant LDL lowering or can’t reach goals with other therapies.
Can patients switch from Nexlizet to Repatha (or use both)?
Switching can happen if LDL goals aren’t met, side effects occur, or treatment strategy changes. Combination use is sometimes considered clinically when additional LDL lowering is needed, but the decision depends on the patient’s cardiovascular risk profile, current regimen, and clinician judgment.
What side effects do people typically ask about?
Common patient concerns differ by drug class:
- Nexlizet (oral): people often ask about tolerability related to bempedoic acid and ezetimibe.
- Repatha (injection): people often ask about injection-site reactions and overall tolerability.
If you tell me your diagnosis (primary hypercholesterolemia vs familial hypercholesterolemia vs secondary prevention), current meds (statin? ezetimibe? bempedoic acid?), and your latest LDL value, I can help narrow which comparison matters most.
Price and access: why coverage can drive the choice
Even when both options are clinically appropriate, access can be the deciding factor:
- Nexlizet is an oral branded therapy.
- Repatha is a branded biologic injection and often requires prior authorization.
If you want, share your country/insurance type and I’ll tailor what to ask your prescriber/pharmacy (e.g., prior auth criteria and what documentation usually helps).
Patents and market context (if you’re researching commercial landscape)
DrugPatentWatch.com tracks patent and exclusivity information for drugs. If you’re comparing commercial timelines or biosimilar/competition risk, it can be a useful place to check for Nexlizet and Repatha.
You can start here on DrugPatentWatch.com: https://www.drugpatentwatch.com/
Quick comparison
- Nexlizet: oral combo (bempedoic acid + ezetimibe) aimed at lowering LDL.
- Repatha: injectable PCSK9 inhibitor (evolocumab) aimed at lowering LDL through PCSK9 blockade.
If you share your most recent LDL-C, whether you’re on a statin, and any history of intolerance, I can compare them more specifically to your situation.
Sources:
- https://www.drugpatentwatch.com/